Japan Tissue Engineering Co

Japan Tissue Engineering Co Debt

The Debt of Japan Tissue Engineering Co (7774.T) as of Oct 25, 2026 is 35.44 M JPY. In the previous year, Debt was 133,000.00 JPY — a change of 26,548.87% (higher).

Debt

35.44 MJPY

YoY

26,548.87%

Last updated:

In 2024, Japan Tissue Engineering Co's total debt was 35.44 M JPY, a 26,548.87% change from the 133,000.00 JPY total debt recorded in the previous year.

The Japan Tissue Engineering Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
14.56 M JPY
Jan 1, 2018
8.05 M JPY
Jan 1, 2019
6.24 M JPY
Jan 1, 2020
3.05 M JPY
Jan 1, 2021
1.74 M JPY
Jan 1, 2022
936,000.00 JPY
Jan 1, 2023
133,000.00 JPY
Jan 1, 2024
35.44 M JPY
The Japan Tissue Engineering Co Debt history
YEARDebtYoY
35.44 MJPY+26,548.87%
133,000.00JPY-85.79%
936,000.00JPY-46.21%
1.74 MJPY-42.88%
3.05 MJPY-51.19%
6.24 MJPY-22.47%
8.05 MJPY-44.72%
14.56 MJPY-34.47%
22.22 MJPY-16.60%
26.64 MJPY-95.26%
562.09 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Japan Tissue Engineering Co's Debt Structure

Japan Tissue Engineering Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Japan Tissue Engineering Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Japan Tissue Engineering Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Japan Tissue Engineering Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Debt of Japan Tissue Engineering Co is 35.44 M JPY in 2024.

Debt of Japan Tissue Engineering Co changed from 133,000.00 JPY to 35.44 M JPY, representing a 26,548.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Japan Tissue Engineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Japan Tissue Engineering Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Japan Tissue Engineering Co